Montserrat Estruch Alrich

Montserrat Estruch Alrich is an Assistant Professor in the Theilgaard Group at the Biotech Research & Innovation Centre (BRIC), University of Copenhagen's Faculty of Health and Medical Sciences. Her research centers on hematopoietic stem cell biology and acute myeloid leukemia (AML) therapeutics, with emphasis on molecular mechanisms of leukemogenesis and novel treatment strategies.

Her primary research interests include hematopoiesis, DNA damage response pathways, and signal transduction in malignancies. She investigates how genetic mutations (e.g., TET2 deficiency) cooperate to induce AML, explores endomucin's role in stem cell migration, and develops inhibitors targeting oxidative stress responses. Current work focuses on overcoming chemotherapy resistance through PI3K/AKT pathway modulation and MTH1 inhibition.

Analysis of her 2021-2024 publications reveals consistent translational focus on AML therapeutics. Key trends include leveraging oxidative DNA damage for selective cancer cell targeting, elucidating mutation-therapy interactions, and developing combination regimens that enhance conventional chemotherapy efficacy. Her work bridges molecular discovery with clinical application, particularly in stem cell migration and nucleotide sanitation pathways.

Scientific awards:

• No awards listed in available data

Advising and grants:

• No student advisement information provided
• No grant details mentioned

Dr. Estruch Alrich operates within the Theilgaard Group at BRIC, a specialized research environment focused on blood cell development and malignancies. The group employs interdisciplinary approaches combining molecular biology, genetics, and translational medicine to address hematopoietic disorders, with direct implications for leukemia diagnostics and therapeutics.